Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatment

Disposition of Comments

Comments received from Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatment.

CYP2D6 for Tamoxifen in Breast Cancer, KRAS for anti-EGFR antibodies in Colorectal Cancer, and BCR-ABL1 for Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Project ID: GENC0609

The Agency for Healthcare Research and Quality's (AHRQ) Technology Assessment (TA) Program supports and is committed to the transparency of its review process. Therefore, invited peer review comments and public review comments are publicly posted on the TA Program Web site at http://www.ahrq.gov/clinic/techix.htm within 3 months after the associated final report is posted.

This document presents the peer review comments and public review comments sent in response to the draft report, Update of Genetic Tests for Non-Cancer and Cancer Diseases and Conditions, which was made available for comment on the AHRQ Web site

Tables

Page last reviewed August 2014
Internet Citation: Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatment: Disposition of Comments. August 2014. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/research/findings/ta/pharmacogenetic-tests/index.html